pharma · Hypercholesterolemia · Hyperlipidemia · ESPR
Esperion Therapeutics
Espervita Therapeutics is a pharma organization headquartered in ann arbor, USA. It trades on NYSE under ticker ESPR. Primary therapeutic focus areas include Hypercholesterolemia, Hyperlipidemia, Cardiovascular Diseases,
Ann Arbor, US HQ
5 Employees
Public company Type
ESPR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ann Arbor, US
- Employees
- 5
- Programs
- 15
- Drugs
- 9
- Patents
- 55
ETC-1002
Phase 2 · small molecule · Hyperlipidemia
ETC-1002 for Hyperlipidemia is a Phase 2 program (small_molecule) at Esperion Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code 1002-005
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Esperion Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Hyperlipidemia
- Status
- completed
- Trials
- 2